Información del artículo
El Texto completo está disponible en PDF
References
[1.]
J.C. Florez.
Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: Where are the insulin resistance genes?.
Diabetologia, 51 (2008), pp. 1100-1110
[2.]
J. Gudmundsson, P. Sulem, V. Steinthorsdottir, J.T. Bergthorsson, G. Thorleifsson, A. Manolescu, et al.
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.
Nat Genet, 39 (2007), pp. 977-983
[3.]
T.M. Frayling, H. Colhoun, J.C. Florez.
A genetic link between type 2 diabetes and prostate cancer.
Diabetologia, 51 (2008), pp. 1757-1760
[4.]
I. Prokopenko, C. Langenberg, J.C. Florez, R. Saxena, N. Soranzo, G. Thorleifsson, et al.
Variants in MTNR1B influence fasting glucose levels.
Nat Genet, 41 (2009), pp. 77-81
[5.]
V. Lyssenko, C.L. Nagorny, M.R. Erdos, N. Wierup, A. Jonsson, P. Spegel, et al.
Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion.
Nat Genet, 41 (2009), pp. 82-88
[6.]
N. Bouatia-Naji, A. Bonnefond, C. Cavalcanti-Proenca, T. Sparso, J. Holmkvist, M. Marchand, et al.
A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk.
Nat Genet, 41 (2009), pp. 89-94
[7.]
C.I.M. Panhuysen, L.A. Cupples, P.W.F. Wilson, A.G. Herbert, R.H. Myers, J.B. Meigs.
A genome scan for loci linked to quantitative insulin traits in persons without diabetes: the Framingham Offspring Study.
Diabetologia, 46 (2003), pp. 579-587
[8.]
R. Sladek, G. Rocheleau, J. Rung, C. Dina, L. Shen, D. Serre, et al.
A genome-wide association study identifies novel risk loci for type 2 diabetes.
Nature, 445 (2007), pp. 828-830
[9.]
Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University and Novartis Institutes for BioMedical Research: Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316:1331- 6.
[10.]
I. Pe’er, P.I.W. De Bakker, J. Maller, R. Yelensky, D. Altshuler, M.J. Daly.
Evaluating and improving power in whole-genome association studies using fixed marker sets.
Nat Genet, 38 (2006), pp. 663-667
[11.]
E. Zeggini, L.J. Scott, R. Saxena, B.F. Voight, J.L. Marchini, T. Hu, et al.
Meta-analysis of genome-wide association data and largescale replication identifies additional susceptibility loci for type 2 diabetes.
Nat Genet, 40 (2008), pp. 638-645
[12.]
S. Kathiresan, O. Melander, C. Guiducci, A. Surti, N.P. Burtt, M.J. Rieder, et al.
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.
Nat Genet, 40 (2008), pp. 189-197
[13.]
P.W. Wilson, J.B. Meigs, L. Sullivan, C.S. Fox, D.M. Nathan, R.B. D’Agostino.
Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study.
Arch Intern Med, 167 (2007), pp. 1068-1074
[14.]
J.B. Meigs, P. Shrader, L.M. Sullivan, J.B. McAteer, C.S. Fox, J. Dupuis, et al.
Genotype score in addition to common risk factors for prediction of type 2 diabetes.
N Engl J Med, 359 (2008), pp. 2208-2219
[15.]
V. Lyssenko, A. Jonsson, P. Almgren, N. Pulizzi, B. Isomaa, T. Tuomi, et al.
Clinical risk factors, DNA variants, and the development of type 2 diabetes.
N Engl J Med, 359 (2008), pp. 2220-2232
[16.]
E.R. Pearson, W.G. Liddell, M. Shepherd, R.J. Corrall, A.T. Hattersley.
Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1a gene mutations: evidence for pharmacogenetics in diabetes.
Diabet Med, 17 (2000), pp. 543-545
[17.]
E.R. Pearson, I. Flechtner, P.R. Njolstad, M.T. Malecki, S.E. Flanagan, B. Larkin, For the Neonatal Diabetes International Collaborative Group, et al.
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
N Engl J Med, 355 (2006), pp. 467-477
[18.]
E.R. Pearson, L.A. Donnelly, C. Kimber, A. Whitley, A.S.F. Doney, M.I. McCarthy, et al.
Variation in TCF7L2 influences therapeutic response to sulfonylureas: A GoDARTs study.
Diabetes, 56 (2007), pp. 2178-2182
[19.]
J.C. Florez, K.A. Jablonski, N. Bayley, T.I. Pollin, P.I.W. De Bakker, A.R. Shuldiner, For the Diabetes Prevention Program Research Group, et al.
TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.
N Engl J Med, 355 (2006), pp. 241-250
[20.]
A.F. Moore, K.A. Jablonski, C.C. Mason, J.B. McAteer, R.F. Arakaki, B.J. Goldstein, et al.
The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the Diabetes Prevention Program.
J Clin Endocrinol Metab, 94 (2009), pp. 449-455
[21.]
M. Bluher, G. Lubben, R. Paschke.
Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes.
Diabetes Care, 26 (2003), pp. 825-831
[22.]
S. Snitker, R.M. Watanabe, I. Ani, A.H. Xiang, A. Marroquin, C. Ochoa, et al.
Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor- γ2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.
Diabetes Care, 27 (2004), pp. 1365-1368
[23.]
J.C. Florez, K.A. Jablonski, M.W. Sun, N. Bayley, S.E. Kahn, H. Shamoon, For the Diabetes Prevention Program Research Group, et al.
effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.
J Clin Endocrinol Metab, 92 (2007), pp. 1502-1509
[24.]
Y. Feng, G. Mao, X. Ren, H. Xing, G. Tang, Q. Li, et al.
Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients.
Diabetes Care, 31 (2008), pp. 1939-1944
[25.]
Y. Shu, S.A. Sheardown, C. Brown, R.P. Owen, S. Zhang, R.A. Castro, et al.
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.
J Clin Invest, 117 (2007), pp. 1422-1431
[26.]
D.J. Hunter, M.J. Khoury, J.M. Drazen.
Letting the genome out of the bottle--will we get our wish?.
N Engl J Med, 358 (2008), pp. 105-107
[27.]
A.F. Moore, J.C. Florez.
Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy.
Annu Rev Med, 59 (2008), pp. 95-111
[28.]
T.M. Frayling.
Genome-wide association studies provide new insights into type 2 diabetes aetiology.
Nat Rev Genet, 8 (2007), pp. 657-662
[29.]
O. Ludovico, F. Pellegrini, R. Di Paola, A. Minenna, S. Mastroianno, M. Cardellini, et al.
Heterogeneous effect of peroxisome proliferator- activated receptor γ2 Ala12 variant on type 2 diabetes risk.
Obesity, 15 (2007), pp. 1076-1081
[30.]
J.C. Florez.
The new type 2 diabetes gene TCF7L2.
Curr Opin Clin Nutr Metab Care, 10 (2007), pp. 391-396
[31.]
J.C. Florez, N. Burtt, P.I.W. De Bakker, P. Almgren, T. Tuomi, J. Holmkvist, et al.
Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region.
Diabetes, 53 (2004), pp. 1360-1368
[32.]
K. Yasuda, K. Miyake, Y. Horikawa, K. Hara, H. Osawa, H. Furuta, et al.
Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus.
Nat Genet, 40 (2008), pp. 1092-1097
Copyright © 2009. Sociedad Española de Endocrinología y Nutrición
